ABBV

ABBV

USD

AbbVie Inc. Common Stock

$215.890+3.520 (1.657%)

リアルタイム価格

Healthcare
Drug Manufacturers - General
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$212.370

高値

$217.080

安値

$212.370

出来高

6.49M

企業ファンダメンタルズ

時価総額

381.4B

業種

Drug Manufacturers - General

United States

取引統計

平均出来高

5.41M

取引所

NYQ

通貨

USD

52週レンジ

安値 $163.81現在値 $215.890高値 $244.81

関連ニュース

Analyst Upgrades

Citigroup Maintains Neutral on AbbVie, Lowers Price Target to $235

Citigroup analyst Geoff Meacham maintains AbbVie with a Neutral and lowers the price target from $240 to $235.

もっと見る
Citigroup Maintains Neutral on AbbVie, Lowers Price Target to $235
Analyst Upgrades

JP Morgan Maintains Overweight on AbbVie, Raises Price Target to $260

JP Morgan analyst Chris Schott maintains AbbVie with a Overweight and raises the price target from $250 to $260.

もっと見る
JP Morgan Maintains Overweight on AbbVie, Raises Price Target to $260
Analyst Upgrades

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

AbbVie beats Q3 estimates with $15.78 billion revenue, boosts dividend to $1.73, raises earnings outlook on strong drug portfolio growth.

もっと見る
AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend
PR Newswire

AbbVie Reports Third-Quarter 2025 Financial Results

AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2025. "AbbVie continues to deliver outstanding results, with ...

もっと見る
AbbVie Reports Third-Quarter 2025 Financial Results
PR Newswire

The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the seventh annual BOTOX® Cosmetic Day will take place on Wednesday, November...

もっと見る
The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year
PR Newswire

AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo

AbbVie (NYSE: ABBV) today announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of upadacitinib...

CNBC

Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings

Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。